Company profile
MiMedx Group, Inc.
NASDAQ: MDXG · Healthcare · Biotechnology
#226 of 1,422 Healthcare companies by revenue66th-percentile growth
EA Score
85AFH 89DQ 87GM 73SS 78
v0.1 · 65/100 weight · provisional
↑ filing timeliness, return on assets · ↓ 3-yr revenue growth, revenue growth (YoY)
Methodology →Revenue TTM
$389.4M
Rev growth YoY (TTM)
+10.5%
Net income (FY)
$48.6M
Employees
808
as of 2026-08-11
Market cap
$622.4M
as of 2026-08-11
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$418.6M$418.6M2025
Net income$48.6M$48.6M2025
Operating income$63.9M$63.9M2025
Total assets$342.7M$342.7M2025
Liabilities$86.1M$86.1M2025
Equity$256.5M$256.5M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Surgical100%
By geography
Not disclosed.
The read
What is MiMedx Group, Inc.’s revenue?
MiMedx Group, Inc. booked $418.6M in FY2025 revenue, growing 20% year over year — faster than most Healthcare companies we track, at a 11.6% net margin.
Peers · Healthcare
Atlantic International Corp.39DGeneDx Holdings Corp.64CCertara, Inc.68BInnoviva, Inc.83B+Ardelyx, Inc.68BEsperion Therapeutics, Inc.61CNeighbors
Cobb →Key facts
CEOJoseph H. Capper
SectorHealthcare
IndustryBiotechnology
HeadquartersMarietta, GA
ExchangeNASDAQ: MDXG
Employees808
IPO date2008-02-12
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.